IF: 1.578
Cite Score:
1.45
THOMSON REUTERS - SCOPUS

Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis

AUTHORS

Serda Gulsun 1 , * , Recep Tekin 2 , Fatma Bozkurt 2

AUTHORS INFORMATION

1 Department of Infectious Diseases and Clinical Microbiology, Diyarbakir State Hospital, serdagulsun@gmail.com, Turkey

2 Department of Infectious Diseases and Clinical Microbiology, Dicle University, Turkey

How to Cite: Gulsun S, Tekin R, Bozkurt F. Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis, Hepat Mon. Online ahead of Print ; 11(9):731-735. doi: 10.5812/kowsar.1735143X.728.

ARTICLE INFORMATION

Hepatitis Monthly: 11 (9); 731-735
Article Type: Research Article
Received: April 5, 2011
Accepted: June 29, 2011
Crossmark

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Chronic delta hepatitis is the most severe form of viral hepatitis, for which interferon administration is the only available treatment. However, the efficacy of interferon treatment is affected by the dose and duration of treatment, and relapse rates are high.
Objectives: In this study, we sought to evaluate the efficacy of treatment with pegylated interferon and observe the relapse rates of delta hepatitis after treatment.
Patients and Methods: Forty-six patients with chronic delta hepatitis were retrospectively studied between January 2002 and December 2010. Patients were evaluated for biochemical, virological, and histological responses. They were then followed-up for at least 1 year after discontinuation of the treatment.
Results: All the 46 patients in the study received PEG-IFN therapy. Of the 46 patients, 25 were treated with PEG-IFN for 1 year and 21 were treated for 2 years. Sixteen patients (34.7%) showed a biochemical response, 27 (58.6%) showed a virological response, and 39 (84.7%) showed a histological response. Sustained virological and biochemical responses were achieved in 41% and 47.8% of the patients, respectively. Sixteen (84.2%) patients of the 19 with high levels of hepatitis delta virus RNA (HDV RNA) (HDV RNA level > 1 × 105) and 10 (71.4%) of the 14 patients with high titers of hepatitis B surface antigen (HbsAg) (HbsAg > 102 IU/mL) at the beginning of the treatment showed relapse after treatment.
Conclusions: We found no significant differences between 1-year and 2-year treatments. However, the relapse rate was lower in the 2-year treatment group. Higher HDV RNA and HbsAg levels before treatment were associated with higher relapse rates. Younger age was a significant factor in predicting response.

Keywords: Chronic delta hepatitis; Pegylated interferon; Treatment


  • Implication for health policy/practice/research/medical education:
    There are still many unresolved questions regarding delta hepatitis. This study aims to investigate every aspect of delta hepatitis and recommended all clinicians engaged in the treatment of patients with hepatitis delta.
  • Please cite this paper as:
    Gulsun S, Tekin R, Bozkurt F. Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis. Hepat Mon. 2011;11(9):731-5. DOI: 10.5812/kowsar.1735143X.728

©2011 Kowsar M.P.Co. All rights reserved.


Keywords

Chronic delta hepatitis Pegylated interferon Treatment

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: